Literature DB >> 20163788

Yohimbine increases impulsivity through activation of cAMP response element binding in the orbitofrontal cortex.

HaoSheng Sun1, Thomas A Green, David E H Theobald, Shari G Birnbaum, Danielle L Graham, Fiona D Zeeb, Eric J Nestler, Catharine A Winstanley.   

Abstract

BACKGROUND: Stress can increase impulsivity and has a negative impact on psychiatric outcome. Norepinephrine is heavily implicated in responses to stress, and the alpha(2) antagonist yohimbine is used clinically to study this aspect of the stress response. Yohimbine induces mild anxiety and increases impulsivity in healthy volunteers but has more detrimental effects in some psychiatric populations, triggering mania in bipolar patients and drug craving in substance-dependent individuals. Understanding the mechanism by which yohimbine affects brain function could provide insight into the heightened reaction to stress in these patients.
METHODS: Yohimbine's effects were assessed in rats using the five-choice serial reaction time test of attention and impulse control. We then examined whether yohimbine altered activity of cyclic adenosine monophosphate response element binding (CREB) protein-a transcription factor implicated in the stress response-in brain areas that regulate impulsivity. The behavioral consequences of any changes in CREB activity were subsequently assessed using viral-mediated gene transfer to regionally overexpress CREB or the dominant negative antagonist mCREB.
RESULTS: Yohimbine increased impulsive responding in rats and selectively increased CREB phosphorylation within the orbitofrontal cortex but not medial prefrontal cortex or nucleus accumbens. Overexpressing mCREB within the orbitofrontal cortex blocked yohimbine's effects on impulsivity, whereas overexpressing CREB in this region increased impulsive responding and potentiated the proimpulsive actions of yohimbine. DISCUSSION: These data suggest a novel molecular mechanism contributing to impulsivity that may be sensitive to stress. Such findings may improve our understanding of the neurobiological pathways linking the response to stress and impulsivity in both healthy and psychiatric populations. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20163788      PMCID: PMC2891518          DOI: 10.1016/j.biopsych.2009.11.030

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  46 in total

1.  Role of cAMP response element-binding protein in the rat locus ceruleus: regulation of neuronal activity and opiate withdrawal behaviors.

Authors:  Ming-Hu Han; Carlos A Bolaños; Thomas A Green; Valerie G Olson; Rachael L Neve; Rong-Jian Liu; George K Aghajanian; Eric J Nestler
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

2.  Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine.

Authors:  Matthew W Feltenstein; Ronald E See
Journal:  Behav Brain Res       Date:  2006-08-21       Impact factor: 3.332

Review 3.  Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder.

Authors:  J R Strawn; T D Geracioti
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

4.  DeltaFosB induction in orbitofrontal cortex mediates tolerance to cocaine-induced cognitive dysfunction.

Authors:  Catharine A Winstanley; Quincey LaPlant; David E H Theobald; Thomas A Green; Ryan K Bachtell; Linda I Perrotti; Ralph J DiLeone; Scott J Russo; William J Garth; David W Self; Eric J Nestler
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

Review 5.  Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function.

Authors:  Avis R Brennan; Amy F T Arnsten
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

6.  Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue.

Authors:  Elena H Chartoff; Maria Papadopoulou; Matt L MacDonald; Aram Parsegian; David Potter; Christine Konradi; William A Carlezon
Journal:  Mol Pharmacol       Date:  2008-12-23       Impact factor: 4.436

7.  CREM mutations and ADHD symptoms.

Authors:  Tuuli A Lahti; Timo Partonen
Journal:  Med Hypotheses       Date:  2009-02-06       Impact factor: 1.538

8.  CREB modulates excitability of nucleus accumbens neurons.

Authors:  Yan Dong; Thomas Green; Daniel Saal; Helene Marie; Rachael Neve; Eric J Nestler; Robert C Malenka
Journal:  Nat Neurosci       Date:  2006-03-05       Impact factor: 24.884

9.  CREB binding and activity in brain: regional specificity and induction by electroconvulsive seizure.

Authors:  Keith Quincy Tanis; Ronald Stanton Duman; Samuel Sathyanesan Newton
Journal:  Biol Psychiatry       Date:  2007-10-15       Impact factor: 13.382

Review 10.  Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies.

Authors:  Catharine A Winstanley; Dawn M Eagle; Trevor W Robbins
Journal:  Clin Psychol Rev       Date:  2006-02-28
View more
  37 in total

1.  Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation.

Authors:  Marieke Soeter; Merel Kindt
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  Overexpression of CREB in the nucleus accumbens shell increases cocaine reinforcement in self-administering rats.

Authors:  Erin B Larson; Danielle L Graham; Rose R Arzaga; Nicole Buzin; Joseph Webb; Thomas A Green; Caroline E Bass; Rachael L Neve; Ernest F Terwilliger; Eric J Nestler; David W Self
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

3.  Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder.

Authors:  Marijn Lijffijt; Brittany O'Brien; Ramiro Salas; Sanjay J Mathew; Alan C Swann
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-18       Impact factor: 6.237

4.  cAMP response element binding protein phosphorylation in nucleus accumbens underlies sustained recovery of sensorimotor gating following repeated D₂-like receptor agonist treatment in rats.

Authors:  Alison K Berger; Thomas Green; Steven J Siegel; Eric J Nestler; Ronald P Hammer
Journal:  Biol Psychiatry       Date:  2010-10-30       Impact factor: 13.382

5.  Effect of yohimbine on reinstatement of operant responding in rats is dependent on cue contingency but not food reward history.

Authors:  Yu-Wei Chen; Kimberly A Fiscella; Samuel Z Bacharach; Gianluigi Tanda; Yavin Shaham; Donna J Calu
Journal:  Addict Biol       Date:  2014-07-27       Impact factor: 4.280

6.  Noradrenergic contributions to cue-driven risk-taking and impulsivity.

Authors:  Chloe S Chernoff; Tristan J Hynes; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2021-03-02       Impact factor: 4.530

7.  Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.

Authors:  Sucharita S Somkuwar; Kathleen M Kantak; Linda P Dwoskin
Journal:  J Neurosci Methods       Date:  2015-02-11       Impact factor: 2.390

8.  Bidirectional pharmacological perturbations of the noradrenergic system differentially affect tactile detection.

Authors:  Jim McBurney-Lin; Yina Sun; Lucas S Tortorelli; Quynh Anh T Nguyen; Sachiko Haga-Yamanaka; Hongdian Yang
Journal:  Neuropharmacology       Date:  2020-05-21       Impact factor: 5.250

9.  Noradrenergic modulation of risk/reward decision making.

Authors:  David R Montes; Colin M Stopper; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

10.  TAAR1 agonists attenuate extended-access cocaine self-administration and yohimbine-induced reinstatement of cocaine-seeking.

Authors:  Jianfeng Liu; Bernard Johnson; Ruyan Wu; Robert Seaman; Jimmy Vu; Qing Zhu; Yanan Zhang; Jun-Xu Li
Journal:  Br J Pharmacol       Date:  2020-05-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.